Description |
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC50=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC50=3.46-5.27 μM for PI3K α/β/γ/K/δ)[1][2].
|
In Vitro |
Orobol binds to CK1ε in an ATP-competitive manner and exerts anti-obesity effects by targeting casein kinase 1 epsilon[2]. Orobol (5-20 μM) effectively suppresses MDI (isobutylmethylxanthine, dexamethasone and insulin (MDI))-induced phosphorylation of 4E-BP1[2].
|
In Vivo |
Orobol attenuates high fat diet-induced weight gain and lipid accumulation without affecting food intake in C57BL/6J mice[2]. Animal Model: HFD-induced obesity in C57BL/6J mice[2] Dosage: 10 mg/kg Administration: Intragastrically; daily for 23 weeks Result: Significantly reduced body weight by 17.3% compared to the HFD group.
|
Density | 1.7±0.1 g/cm3 |
Boiling Point | 616.1±55.0 °C at 760 mmHg |
Flash Point | 239.5±25.0 °C |
Exact Mass | 286.047729 |
PSA | 111.13000 |
LogP | 2.76 |
Vapour Pressure | 0.0±1.8 mmHg at 25°C |